In this article, we will look at the 10 Best Dip Stocks to Buy According to Billionaires.
On July 3rd, Dan Ives, Global Head of Tech Research at Wedbush, joined CNBC to discuss the technology sector. He notes that AI will fuel a multi-year tech rally and that rally is just beginning as the sector made a comeback from the liberation day. Ives highlighted that the tech stocks have been up 10% to 15% in the second half of the year, and this is because the second and third derivatives of AI have started to play out. Ives believes that the AI play has led the NASDAQ 100 to high range of 22,000 to 23,0000.
While addressing a question regarding the potential downsides for the sector down the road, Ives noted that he sees the turbulence from future trade deals, Fed meetings, or geopolitical situations as buying opportunities. He elaborated that as long as the fundamentals remain stable for the tech sector, he sees at least a 3-year tech bull market ahead.
Ives also shared his opinion on the high valuations of some technology stocks. He noted that investors need to segregate transformational tech stocks from ordinary tech stocks. He added, while the market sees some of the transformational tech stocks to be over-valued, Ives sees them as undervalued due to their long-term role in the AI revolution. Ives likes the software and cybersecurity stocks to be some of the most transformational sectors within the industry.
With that, let’s take a look at the 10 best dip stocks to buy according to billionaires.
An experienced financial trader seated at a desk, poring over a stack of graphs.
Our Methodology
To curate the list of 10 best dip stocks to buy according to billionaires, we used the Finviz Stock Screener and Yahoo Finance. Using the screener, we aggregated a list of tech stocks trading within 0%-10% of their 52-week lows. Next, we cross-checked the 52-week range for each stock from Yahoo Finance. Lastly, we ranked the stocks in ascending order of the number of billionaire investors as of Q4 2024, sourced from Insider Monkey’s database. We have also added the number of hedge funds holding each stock as of Q1 2025. Please note that the data was recorded on June 30, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Best Dip Stocks to Buy According to Billionaires
10. Sanofi (NASDAQ:SNY)
Price: $47.85
52 Week Range: $45.80 – $60.12
Number of Hedge Fund Holders: 27
Number of Billionaire Investors: 7
Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) announced that the FDA granted orphan drug designation to Riliprubart for treating antibody-mediated rejection in solid organ transplantation.
The FDA grants orphan drug designation to drugs aimed at treating rare diseases or conditions affecting fewer than 200,000 people in the US. This is a significant milestone for Sanofi (NASDAQ:SNY) as it provides benefits including tax credits, user fee waivers, and market exclusivity upon approval.
Riliprubart is currently being evaluated in multiple clinical trials across different indications, including transplant and neurology. The phase 2 study is underway to assess its efficacy in kidney transplant recipients. Sanofi (NASDAQ:SNY) is also conducting two phase 3 trials investigating Riliprubart in chronic inflammatory demyelinating polyneuropathy.
Sanofi (NASDAQ:SNY) is a leading healthcare company headquartered in France. It focuses on improving patient health through the research, development, manufacturing, and marketing of a wide range of therapeutic solutions.
9. Lowe’s Companies, Inc. (NYSE:LOW)
Price: $223.63
52 Week Range: $206.39 – $287.01
Number of Hedge Fund Holders: 68
Number of Billionaire Investors: 14
Lowe’s Companies, Inc. (NYSE:LOW) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 23, analyst Zachary Fadem from Wells Fargo reduced the price target on Lowe’s Companies, Inc. (NYSE:LOW) from $300 to $260, while reiterating a Buy rating on the stock. The rating comes after the company posted mixed results for its Q1 2025.
Lowe’s Companies, Inc. (NYSE:LOW) posted a revenue of $20.93 billion, reflecting a 2.03% decline year-over-year and below expectations by $29.64 million. However, the EPS of $2.92 topped the analysts’ target by $0.04. Management noted the decrease in comparable sales to be impacted by the unfavorable weather conditions early in the quarter, but was partially offset by mid-single-digit growth in professional and online sales.
Despite the mixed results, Lowe’s Companies, Inc. (NYSE:LOW) reaffirmed its fiscal 2025 guidance and continues to expect sales ranging from $83.5 billion to $84.5 billion with comparable sales in a range of flat to up 1%. The operating margin is expected to be in the range of 12.3% to 12.4%.
Lowe’s Companies, Inc. (NYSE:LOW) is a leading home improvement retailer. Its services and products range from construction, maintenance, repair, remodeling, and decorating projects.
8. Accenture plc (NYSE:ACN)
Price: $295.46
52 Week Range: $273.19 – $398.35
Number of Hedge Fund Holders: 69
Number of Billionaire Investors: 14
Accenture plc (NYSE:ACN) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 30, Accenture plc (NYSE:ACN) announced its partnership with Palantir Technologies Inc. (NASDAQ:PLTR) to deliver advanced AI-powered solutions to US federal government agencies.
As part of the partnership, Accenture Federal Services, which is a subsidiary of Accenture plc (NYSE:ACN), has been named Palantir’s preferred implementation partner for deploying its AI platforms to federal customers. Accenture Federal will train and certify 1,000 of its Data & AI professionals on Palantir’s Foundry and Artificial Intelligence Platform. The company will also build a large-scale joint delivery team focused on AI automation in government.
Some of the initial joint offerings by both companies include Enterprise-to-Edge data fusion, predictive supply chain orchestration, and operationalized financial intelligence.
Accenture plc (NYSE:ACN) is a leading international professional services company that helps organizations improve their performance. The company operates through key areas including Strategy and Consulting, Technology, Operations, and Industry X.
7. PepsiCo, Inc. (NASDAQ:PEP)
Price: $131.04
52 Week Range: $127.60 – $180.91
Number of Hedge Fund Holders: 71
Number of Billionaire Investors: 14
PepsiCo, Inc. (NASDAQ:PEP) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 27, Deutsche Bank released a note regarding PepsiCo, Inc. (NASDAQ:PEP), highlighting that the company needs to win investor confidence as its current strategy is under question due to dropping snack consumption trends in the US.
PepsiCo, Inc. (NASDAQ:PEP) is set to release its Q2 2025 results on July 17. Deutsche Bank analyst Steve Powers noted that with the earnings call approaching, the company needs to show some increased sense of urgency to gain investor confidence. He added that although the bank continues to believe that the intrinsic value of PepsiCo, Inc. (NASDAQ:PEP) exceeds its current trading value, the declining consumption trends in the US have disappointed the bull case for the company.
Powers noted that the upcoming earnings call will be important for the company as it should point to some meaningful conversation regarding how the future will be different from the past.
6. Chevron Corporation (NYSE:CVX)
Price: $143.79
52 Week Range: $132.04 – $168.96
Number of Hedge Fund Holders: 81
Number of Billionaire Investors: 14
Chevron Corporation (NYSE:CVX) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On July 2nd, Bloomberg reported that Chevron Corporation (NYSE:CVX) is one of the 37 global energy firms competing in Libya’s first oil and gas exploration tender since the 2011 conflict that toppled Muammar Qaddafi.
The tender is a significant milestone for oil companies as Libya holds Africa’s largest proven oil reserves. Libya, seeks to restore and boost its battered oil sector after more than a decade of instability and conflict. The country aims to increase its daily oil production to 2 million barrels by 2030, surpassing the previous peak of 1.75 million barrels in 2006 under Qaddafi’s rule.
The report highlighted that Chevron Corporation (NYSE:CVX), along with TotalEnergies SE, Eni SpA, Exxon Mobil, and other major international oil companies, have expressed interest in acquiring exploration rights for 22 offshore and onshore blocks. Contracts with successful bidders are expected to be signed by the end of 2025.
Chevron Corporation (NYSE:CVX) is one of the world’s largest integrated energy companies, operating across the entire energy value chain. Its activities span from the exploration and production of raw energy resources to the delivery of refined products and advanced energy solutions.
5. The Procter & Gamble Company (NYSE:PG)
Price: $159.86
52 Week Range: $156.58 – $180.43
Number of Hedge Fund Holders: 88
Number of Billionaire Investors: 14
The Procter & Gamble Company (NYSE:PG) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 5, Reuters reported that The Procter & Gamble Company (NYSE:PG) is expected to cut 7,000 jobs over the next two years. This comes as a response to the challenges from the uncertain spending environment in the United States due to the tariffs.
The Procter & Gamble Company (NYSE:PG) is also expected to exit some product categories and brands, with anticipated divestitures in certain markets. The job cut of 7,000 represents around 6% of its total workforce. Management has characterized it as part of its ongoing strategy and two-year restructuring program.
The Procter & Gamble Company (NYSE:PG) is a leading global consumer company that provides branded daily life products. The company operates through five main segments which include Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine, and Family Care.
4. Amgen Inc. (NASDAQ:AMGN)
Price: $277.13
52 Week Range: $253.30 – $346.85
Number of Hedge Fund Holders: 96
Number of Billionaire Investors: 14
Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 30, Amgen Inc. (NASDAQ:AMGN) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers.
The company announced that the Phase 3 FORTITUDE-101 trial met its primary endpoint. The Bemarituzumab plus chemotherapy significantly improved overall survival in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer with FGFR2b overexpression and who are non-HER2 positive.
Gastric cancer is the fifth leading cause of cancer-related death globally, with nearly 1 million new cases and over 650,000 deaths each year. Bemarituzumab is a first-in-class, Fc-optimized monoclonal antibody that targets FGFR2b, a protein overexpressed in a subset of gastric cancers. Management noted that detailed results will be presented in future meetings, and a separate Phase 3 trial of Bemarituzumab plus chemotherapy and nivolumab is ongoing, with results expected in the second half of 2025.
Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that develops innovative medicines for serious diseases with limited treatments.
3. Johnson & Johnson (NYSE:JNJ)
Price: $152.41
52 Week Range: $140.68 – $169.99
Number of Hedge Fund Holders: 91
Number of Billionaire Investors: 18
Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 26, J.P. Morgan analyst Chris Schott maintained their Hold Rating on Johnson & Johnson (NYSE:JNJ) with a price target of $185.
Schott acknowledged that the company’s underlying business is well-positioned for over 5% sustained top-line growth, driven by the company’s innovative medicine and meditech portfolio. However, he also noted some key challenges that temper his optimism. Schott highlighted the erosion of Stelara sales due to biosimilar competition, which he believes is expected to negatively impact growth.
Moreover, the ongoing talc litigation remains a significant overhang. And lastly, the pharmaceutical portfolio is forecasted to remain flat year-over-year, with notable declines in drugs like Stelara. As a result of these challenges, Schott remains cautiously optimistic about Johnson & Johnson (NYSE:JNJ).
2. Merck & Co., Inc. (NYSE:MRK)
Price: $79.10
52 Week Range: $73.31 – $129.93
Number of Hedge Fund Holders: 93
Number of Billionaire Investors: 16
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On July 2, Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted and granted priority review to its supplemental Biologics License Application for WINREVAIR.
Merck & Co., Inc.’s (NYSE:MRK) WINREVAIR was previously approved in 2024 for treating adults with pulmonary arterial hypertension. The treatment aims to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The current application seeks to update the US product label based on the results of the Phase 3 ZENITH trial.
The ZENITH trial is notable for being the first Phase 3 PAH study to use a primary endpoint focused solely on major morbidity and mortality events. The results demonstrated a 76% reduction in the risk of a composite outcome of all-cause death, lung transplantation, and hospitalization for PAH lasting 24 hours or more, compared to placebo. The FDA has set a target action date of October 25, 2025, under the Prescription Drug User Fee Act.
Merck & Co., Inc. (NYSE:MRK) is a leading healthcare company that operates through two main segments including the Pharmaceutical and Animal Health Segments.
1. Thermo Fisher Scientific Inc. (NYSE:TMO)
Price: $408.28
52 Week Range: $385.46 – $627.88
Number of Hedge Fund Holders: 101
Number of Billionaire Investors: 16
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On July 3, Thermo Fisher Scientific Inc. (NYSE:TMO) announced receiving FDA approval for its Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer.
After the approval, this test is now authorized as an in vitro diagnostic and as a companion diagnostic for Dizal’s ZEGFROVY. ZEGFROVY is a targeted therapy for non-small cell lung cancer patients with EGFR exon 20 insertion mutations. The test is also approved for broader tumor profiling in solid tumors, detecting mutations across 46 genes with clinical or potential clinical significance.
This is a significant achievement as it brings rapid next-generation sequencing closer to patients. The technology can deliver crucial genomic results in as little as 24 hours. This speed is important for cancer care, as delays in obtaining tumor profiles can prevent patients from receiving timely treatments.
Thermo Fisher Scientific Inc. (NYSE:TMO) is a healthcare company that is focused on accelerating research, solving complex analytical problems, boosting laboratory efficiency, and improving patient health.
While we acknowledge the potential of TMO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TMO and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
